article Open AccessTop 1% cited

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

JNCI Journal of the National Cancer Institute · 1998 · Vol. 90(18) · pp. 1371–1388

Bernard Fisher✉(Allegheny College)Joseph P. Costantino(University of Pittsburgh)D. Lawrence Wickerham(Allegheny General Hospital)Carol RedmondMaureen KavanahWalter M. Cronin(University of Pittsburgh)Victor G. Vogel(University of Pittsburgh)André RobidouxNikolay DimitrovJames N. AtkinsMary B. DalySamuel WieandElizabeth Tan-ChiuLeslie G. FordNorman Wolmarkother National Surgical Adjuvant BreastBowel Project Investigators

View via DOI Full-text PDF

Abstract

Tamoxifen decreases the incidence of invasive and noninvasive breast cancer. Despite side effects resulting from administration of tamoxifen, its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.

Breast Cancer Treatment Studies Estrogen and related hormone effects Cancer Risks and FactorsTamoxifenMedicineBreast cancerLobular carcinomaCumulative incidenceOncologyGynecologyInternal medicineCancerIncidence (geometry)

MeSH terms

AdultBreast NeoplasmsCause of DeathEstrogen AntagonistsFemaleHumansMiddle AgedNeoplasm InvasivenessQuality of LifeRiskRisk FactorsTamoxifenOdds RatioTreatment OutcomeAntineoplastic Agents, Hormonal

Funding

U.S. Department of Health and Human Services
Wayne State University
University of Pennsylvania
Ohio State University
Texas Tech University
Michigan State University
Johns Hopkins University
University of Cincinnati
University of South Alabama
Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Women's College Hospital
National Institutes of Health
College of Engineering, Michigan State University
University of California, Los Angeles
University of North Carolina at Chapel Hill
National Cancer Institute